Cell/Gene Tx channel feed

Spark los­es an­oth­er top ex­ec in the wake of $4.3B takeover by Roche — re­port

6 years ago
People

'The head­lines are the head­lines, but': Bio­Marin talks up po­ten­tial sav­ings as he­mo­phil­ia gene ther­a­py launch looms

6 years ago

Will a 'risk-of­f' mind­set has­ten cell ther­a­py M&A? Io­vance surges on buy­out chat­ter

6 years ago
Deals

Bio­gen touts new ev­i­dence from the gene ther­a­py com­pa­ny it wa­gered $800M on

6 years ago
R&D

Speedy re­view and no ad­comm for Bio­Mar­in's pi­o­neer­ing he­mo­phil­ia gene ther­a­py

6 years ago
FDA+

Gene ther­a­py pi­o­neer Kathy High has left Spark af­ter com­plet­ing $4.3B union with Roche

6 years ago
People

TCR-fo­cused Im­mat­ics adds an­oth­er mar­quee name to its list of part­ners: GSK

6 years ago
Deals

FDA slaps a hold on Log­icBio and its gene edit­ing plans — shares tum­ble

6 years ago
FDA+

From mice to dogs, and some­day man: George Church's gene ther­a­py cock­tail for ag­ing-re­lat­ed dis­eases

6 years ago
Startups
R&D

Kym­ri­ah pi­o­neer Carl June is back, with first US hu­man ev­i­dence for CRISPR use in can­cer

6 years ago

MD An­der­son emerges with strong ev­i­dence for nat­ur­al killer cell ther­a­py, and Take­da looks like a win­ner

6 years ago
R&D

How much does it cost to boot­strap a gene ther­a­py start­up? Not too much if you're Jim Wil­son, per Pas­sage Bio's $125M IPO fil­ing

6 years ago
Financing

Catal­ent chief John Chimin­s­ki trig­gers a $315M-plus wa­ger on the boom­ing cell ther­a­py mar­ket now in the mak­ing

6 years ago
Deals
Outsourcing

Re­sis­tant to CAR-T ther­a­pies? It's the can­cer, not your im­mune sys­tem — study

6 years ago
R&D

Eye­ing a trio of tri­al ini­ti­a­tions, Jim Wilson's gene ther­a­py start­up woos Bruce Gold­smith from Deer­field as CEO

6 years ago
People

Deer­field vaults to the top of cell and gene ther­a­py CD­MO game with $1.1B fa­cil­i­ty at Philadel­phi­a's newest bio­phar­ma hub

6 years ago
Outsourcing

At #JPM20, two CEOs, two rad­i­cal­ly dif­fer­ent ther­a­pies, and a fight to chase down sick­le cell

6 years ago
R&D
In Focus

With $110M to add to the bankroll, Gen­er­a­tion Bio sets its sights on en­gi­neer­ing a rev­o­lu­tion in the gene ther­a­py field

6 years ago
Financing

Chi­nese court sen­tences Jiankui He to 3 years in jail — and con­firms birth of 3rd CRISPR ba­by

6 years ago
China

Flag­ship bankrolls quest to cre­ate gene ther­a­py 2.0, with new vi­ral de­liv­ery tech in hand

6 years ago
Financing
Startups

In­side Astel­las' $3B Au­dentes gene ther­a­py ac­qui­si­tion: cod­ed mes­sages, a bid­ding war and $77M for the CEO

6 years ago
Deals

UK an­titrust watch­dog clears Roche/Spark deal — but what is the FTC think­ing?

6 years ago
Deals

Ju­ry finds Gilead li­able for $585M and big roy­al­ties in Kite CAR-T patent case

6 years ago

Kite Phar­ma's ex-CEO con­tra­dicts founder as CAR-T patent tri­al heats up, with con­flict­ing val­u­a­tions

6 years ago
First page Previous page 48495051525354 Next page Last page
A service from the Financial Times